Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.65 |
| ▸ | SLC5A2 | P31639 | 9/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL6397602 | 0.92 | P2RY2 (0.60) | P2RY2NPC1RAB9ASMN1; SMN2P2RY4 | |
| SCHEMBL6400576 | 0.84 | P2RY2 (0.83) | P2RY2CYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL6395255 | 0.82 | P2RY2 (0.62) | P2RY2SLC5A2CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL6395173 | 0.80 | P2RY2 (0.60) | P2RY2SLC5A2P2RY4 | |
| SCHEMBL7048838 | 0.80 | P2RY2 (0.60) | P2RY2SLC5A2P2RY4 | |
| Phosphoric Acid SCHEMBL6400578 | 0.80 | P2RY2 (0.63) | P2RY2CYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL6400565 | 0.80 | P2RY2 (1.00) | P2RY2P2RY4 | |
| SCHEMBL6395681 | 0.76 | P2RY2 (0.62) | P2RY2SLC5A2P2RY4 | |
| SCHEMBL6393322 | 0.75 | P2RY2 (0.64) | P2RY2SLC5A2CYP3A4DYRK1A | |
| Benzoic Acid SCHEMBL6395749 | 0.75 | P2RY2 (0.57) | P2RY2SLC5A2NPC1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009777-A1 | Non-natural carbon-linked nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1409503-A1 | NON-NATURAL CARBON-LINKED NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003011885-A1 | NON-NATURAL CARBON-LINKED NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009777-A1 | Non-natural carbon-linked nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | P2RY2 4/4885SLC5A2 45/4885CYP1A2 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.